BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

 

Real World Experience with BRILIQUE from key experts

We invite you to visit the Calibre Portal Website which provides a bespoke calibre of educational videos and resources for peer-to-peer scientific education to share best practice. The website aims to support you in the treatment of your ACS patients, for healthcare professionals involved in the ACS care pathway in cardiology and payers with budget responsibilities in cardiology.

The portal provides a bespoke calibre of educational videos and resources for peer-to-peer scientific education for ACS healthcare professionals to share best practice.

The management of high-risk post myocardial infarction (MI) patients transitioning from secondary to primary care

Click the image below to watch an educational video from Professor Ahmet Fuat